The Pharmacokinetic Profile of Voriconazole During Continuous High-volume Venovenous Hemofiltration in a Critically Ill Patient
暂无分享,去创建一个
S. Lasocki | H. Quintard | P. Arnaud | P. Montravers | J. Desmonts | L. Massias | E. Papy
[1] M. Shimizu,et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. , 2007, Biochemical pharmacology.
[2] L. Gordon,et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.
[3] D. Schaer,et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.
[4] J. Burhenne,et al. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy , 2006, BMC clinical pharmacology.
[5] G. Mikus,et al. Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype , 2006, Antimicrobial Agents and Chemotherapy.
[6] D. Andes,et al. Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.
[7] W. Salzer,et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] T. Buclin,et al. Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. , 2004, The Journal of antimicrobial chemotherapy.
[9] N. Wood,et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. , 2003, British journal of clinical pharmacology.
[10] C. A. Kauffman,et al. Voriconazole: a new triazole antifungal agent. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[12] N. Wood,et al. Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.
[13] E. Thiel,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] D. Stopher,et al. A rapid HPLC assay for voriconazole in human plasma. , 1998, Journal of pharmaceutical and biomedical analysis.
[15] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.
[16] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.
[17] A. Grootendorst,et al. High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig , 2005, Intensive Care Medicine.
[18] A. Sitges-Serra,et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy , 1997, Intensive Care Medicine.